# Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura

> **NCT00107913** · PHASE2 · UNKNOWN · sponsor: **Hematology and Oncology Specialists** · enrollment: 10 (—)

## Conditions studied

- Autoimmune Thrombocytopenic Purpura

## Interventions

- **DRUG:** Doxil

## Key facts

- **NCT ID:** NCT00107913
- **Lead sponsor:** Hematology and Oncology Specialists
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2001-09
- **Primary completion:** —
- **Final completion:** 2005-04
- **Target enrollment:** 10 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00107913

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00107913, "Study of Doxil in the Treatment of Patients With Refractory Idiopathic Thrombocytopenic Purpura". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00107913. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*